Premium
Tumor vaccination against hepatoma: How does it work?
Author(s) -
Hanada Shuichi,
Wakita Takaji,
Takahashi Hiroshi
Publication year - 1994
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840200540
Subject(s) - immunotherapy , hepatocellular carcinoma , cd8 , immune system , vaccination , immunity , cancer immunotherapy , cytotoxic t cell , cancer research , immunology , medicine , biology , in vitro , biochemistry
Fusion of BERH‐2 rat hepatocellular carcinoma cells with activated B cells produced hybrid cells that lost their tumorigenicity and became immunogenic. Syngeneic rats injected with BERH‐2‐B hybrid cells became resistant to challenge with parental BERH‐2 cells, and rats with established BERH‐2 hepatomas were cured by subsequent injection of BERH‐2‐B cells. Both CD4 and CD8 + cells were essential for the induction of protective immunity; however, only CD8 + cells were required for the eradication of BERH‐2 tumors. The generation of hybrid tumor cells that elicit antitumor immune responses may be a useful strategy for cancer immunotherapy.